Citigroup’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-45,000
| Closed | -$358K | – | 5871 |
|
|
2025
Q1 | $358K | Buy |
45,000
+5,100
| +13% | +$37.3K | ﹤0.01% | 3856 |
|
|
2024
Q4 | $217K | Hold |
39,900
| – | – | ﹤0.01% | 4368 |
|
|
2024
Q3 | $288K | Sell |
39,900
-6,800
| -15% | -$62.3K | ﹤0.01% | 4099 |
|
|
2024
Q2 | $507K | Buy |
+46,700
| New | +$598K | ﹤0.01% | 3387 |
|
|
2023
Q3 | – | Sell |
-20,000
| Closed | -$940K | – | 5790 |
|
|
2023
Q2 | $940K | Hold |
20,000
| – | – | ﹤0.01% | 2891 |
|
|
2023
Q1 | $839K | Buy |
+20,000
| New | +$860K | ﹤0.01% | 2688 |
|
|
2022
Q1 | – | Sell |
-50,000
| Closed | -$2.13M | – | 6570 |
|
|
2021
Q4 | $2.13M | Buy |
+50,000
| New | +$2.09M | ﹤0.01% | 2575 |
|
|
2021
Q1 | – | Sell |
-41,500
| Closed | -$3.59M | – | 7220 |
|
|
2020
Q4 | $3.59M | Buy |
41,500
+13,600
| +49% | +$1M | ﹤0.01% | 2332 |
|
|
2020
Q3 | $1.71M | Sell |
27,900
-11,300
| -29% | -$573K | ﹤0.01% | 2792 |
|
|
2020
Q2 | $1.63M | Buy |
39,200
+4,200
| +12% | +$152K | ﹤0.01% | 3041 |
|
|
2020
Q1 | $1M | Sell |
35,000
-29,700
| -46% | -$1.72M | ﹤0.01% | 3172 |
|
|
2019
Q4 | $4.67M | Buy |
64,700
+34,400
| +114% | +$4.23M | ﹤0.01% | 2076 |
|
|
2019
Q3 | $4.25M | Sell |
30,300
-20,300
| -40% | -$3.4M | ﹤0.01% | 2083 |
|
|
2019
Q2 | $9.26M | Sell |
50,600
-1,700
| -3% | -$290K | 0.01% | 1448 |
|
|
2019
Q1 | $8.32M | Buy |
52,300
+7,600
| +17% | +$1.1M | 0.01% | 1397 |
|
|
2018
Q4 | $4.28M | Sell |
44,700
-5,000
| -10% | -$572K | ﹤0.01% | 1950 |
|
|
2018
Q3 | $7.02M | Buy |
49,700
+21,400
| +76% | +$3.3M | 0.01% | 1547 |
|
|
2018
Q2 | $4.43M | Sell |
28,300
-300
| -1% | -$47.1K | ﹤0.01% | 1949 |
|
|
2018
Q1 | $4.61M | Sell |
28,600
-24,200
| -46% | -$4.11M | ﹤0.01% | 1843 |
|
|
2017
Q4 | $8.7M | Buy |
52,800
+41,300
| +359% | +$4M | 0.01% | 1392 |
|
|
2017
Q3 | $716K | Sell |
11,500
-47,300
| -80% | -$3.71M | ﹤0.01% | 3722 |
|
|
2017
Q2 | $4.68M | Sell |
58,800
-6,500
| -10% | -$470K | ﹤0.01% | 1746 |
|
|
2017
Q1 | $4.64M | Buy |
65,300
+55,800
| +587% | +$3.27M | ﹤0.01% | 1729 |
|
|
2016
Q4 | $485K | Buy |
+9,500
| New | +$448K | ﹤0.01% | 4409 |
|
Other funds holding SAGE
IA
HNB
Citigroup's SAGE Position: Q3 2025 in Review
Citigroup sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 47,849 shares — an estimated $436K sold.
Citigroup first reported a position in SAGE in Q3 2014 and held it in 44 quarters. The position peaked at $12.1M in Q4 2016. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.
- Citigroup reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
- Citigroup sold 47,849 Sage Therapeutics shares in Q3 2025, an estimated $436K.
- Citigroup first reported a position in Sage Therapeutics in Q3 2014 and held it in 44 quarters.
- Citigroup's Sage Therapeutics position peaked at $12.1M in Q4 2016.
- 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.
Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.